These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36760562)

  • 21. Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis.
    Xie Q; Xiang Q; Liu Z; Mu G; Zhou S; Zhang Z; Ma L; Gong Y; Jiang J; Cui Y
    BMC Cardiovasc Disord; 2022 Mar; 22(1):111. PubMed ID: 35300607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
    Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary intervention and stenting receiving clopidogrel.
    Chen YW; Liao YJ; Chang WC; Hsiao TH; Lin CH; Hsu CY; Liu TJ; Lee WL; Chen YM
    Front Cardiovasc Med; 2022; 9():994184. PubMed ID: 36072879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2C19 polymorphisms and clopidogrel efficacy in the secondary prevention of ischemic stroke: a retrospective observational study.
    Lin J; Mo Y; Cai D; Mao D; Fu H; Wei D
    Ann Palliat Med; 2021 Dec; 10(12):12171-12180. PubMed ID: 35016407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.
    Wang JY; Zhang YJ; Li H; Hu XL; Li MP; Song PY; Ma QL; Peng LM; Chen XP
    Gene; 2018 Dec; 678():226-232. PubMed ID: 30096456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.
    Zhu KX; Song PY; He-Li ; Li MP; Du YX; Ma QL; Peng LM; Chen XP
    Eur J Clin Pharmacol; 2021 Mar; 77(3):359-368. PubMed ID: 33089397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis.
    Biswas M; Kali SK
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1147-1159. PubMed ID: 33523336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of major adverse cardiovascular events of
    Biswas M; Kali MSK; Biswas TK; Ibrahim B
    Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
    Jiang M; You JH
    Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Chanfreau-Coffinier C; Friede KA; Plomondon ME; Lee KM; Lu Z; Lynch JA; DuVall SL; Vassy JL; Waldo SW; Cleator JH; Maddox TM; Rader DJ; Assimes TL; Damrauer SM; Tsao PS; Chang KM; Voora D; Giri J; Tuteja S
    medRxiv; 2023 Oct; ():. PubMed ID: 37961335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
    Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
    Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
    Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis.
    Jafrin S; Naznin NE; Reza MS; Aziz MA; Islam MS
    Eur J Intern Med; 2021 Aug; 90():49-65. PubMed ID: 34092486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
    Jang JS; Cho KI; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Seol SH; Kim DI; Kim BH; Park YH; Je HG; Jeong YH; Lee SW
    Am J Cardiol; 2012 Aug; 110(4):502-8. PubMed ID: 22591668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial.
    Park KW; Park JJ; Lee SP; Oh IY; Suh JW; Yang HM; Lee HY; Kang HJ; Cho YS; Koo BK; Youn TJ; Chae IH; Choi DJ; Oh BH; Park YB; Kim HS
    Heart; 2011 Apr; 97(8):641-7. PubMed ID: 21345843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunction are significantly correlated with adverse cardiovascular events following coronary stent implantation.
    Tabata N; Hokimoto S; Akasaka T; Arima Y; Sakamoto K; Yamamoto E; Tsujita K; Izumiya Y; Yamamuro M; Kojima S; Kaikita K; Kumagae N; Morita K; Oniki K; Nakagawa K; Matsui K; Ogawa H
    J Cardiol; 2016 Jan; 67(1):104-9. PubMed ID: 25851472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.
    Martin J; Williams AK; Klein MD; Sriramoju VB; Madan S; Rossi JS; Clarke M; Cicci JD; Cavallari LH; Weck KE; Stouffer GA; Lee CR
    Genet Med; 2020 Jan; 22(1):160-169. PubMed ID: 31316169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.